๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of myelodysplastic syndrome with 1.25-dihydroxy-vitamin D3

โœ Scribed by Dr. C. Richard; E. Mazo; M. A. Cuadrado; A. Iriondo; C. Bello; M. A. Gandarillas; A. Zubizarreta


Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
200 KB
Volume
23
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


1ฮฑ,25-Dihydroxy-3-Epi-vitamin D3, a natu
โœ A.J. Brown; C. Ritter; E. Slatopolsky; K.R. Muralidharan; W.H. Okamura; G.S. Red ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 130 KB

1โฃ,25(OH) 2 D 3 is an important negative regulator of parathyroid hormone (PTH) gene transcription. In parathyroid cells, as in other target tissues, 1โฃ,25(OH) 2 D 3 is degraded by side chain oxidation by the inducible 24-hydroxylase. We have previously shown that one metabolite of this pathway, 1โฃ,

Three-dimensional model of the ligand bi
โœ Anthony W. Norman; Derk Adams; Elaine D. Collins; William H. Okamura; Robert J. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 449 KB ๐Ÿ‘ 1 views

A three-dimensional model for residues 142-427 of the ligand binding domain (LBD) of the human nuclear receptor for 1โฃ,25-dihydroxy-vitamin D 3 [VDR] has been generated based on the X-ray crystallographic atomic coordinates of the LBD of the rat โฃ1 thyroid receptor (TR). The VDR LBD model is an elon